Abstract Number: 944 • 2014 ACR/ARHP Annual Meeting
Predict the Chance of Remission for Your RA Patient in Real Life
Background/Purpose: Clinical remission (REM) is the treatment target in rheumatoid arthritis (RA), and there are several composite REM criteria available. Knowledge on how disease duration affects REM…Abstract Number: 1334 • 2013 ACR/ARHP Annual Meeting
Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial
Background/Purpose: Radiographic progression is a key outcome in early RA. We previously developed a radiographic progression prediction method based on the patient’s report of symptom…Abstract Number: 997 • 2013 ACR/ARHP Annual Meeting
Does Biologic Treatment For Rheumatoid Arthritis Offset Health Care Costs In Patients With Rheumatoid Arthritis? An Instrumental Variable Approach Using Administrative Data
Background/Purpose: Expenditure on biologic therapies for rheumatoid arthritis (RA) accounts for the highest pharmaceutical spending in many western healthcare systems. Given their clinical benefit with…Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…Abstract Number: 2808 • 2013 ACR/ARHP Annual Meeting
Favorable Outcome Of Hepatitis E Virus Infection In Patients With Inflammatory Arthritides Treated With Immunosupressants
Background/Purpose: In inflammatory rheumatic diseases, the prevalence, clinical presentation and outcome of hepatitis E, an ubiquitous viral infection, remain unknown. We therefore addressed these issues…Abstract Number: 328 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Background/Purpose: The use of biologic therapy in psoriatic arthritis (PsA) has altered the disease course and has been shown to reduce disease activity. Data comparing…Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…Abstract Number: 2378 • 2013 ACR/ARHP Annual Meeting
Safety Of Mavrilimumab In Cynomolgus Monkeys: Relevance Of Nonclinical Findings In Lung To Human Safety
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils. Mavrilimumab (CAM-3001)…Abstract Number: 2360 • 2013 ACR/ARHP Annual Meeting
Incidence Of Diabetes and Effect Of Etanercept and Adalimumab On HbA1c Over 1 Year: Data From a Randomised Trial In Patients With Rheumatoid Arthritis
Background/Purpose: Inflammation such as that which occurs in rheumatoid arthritis (RA) is associated with insulin resistance and risk of diabetes mellitus (DM). Some DMARDs including…Abstract Number: 2316 • 2013 ACR/ARHP Annual Meeting
Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Background/Purpose: The cytokine tumor necrosis factor (TNF)alpha is a potent pro-inflammatory mediator involved in several autoimmune diseases including rheumatic arthritis and for over a decade…Abstract Number: 1913 • 2013 ACR/ARHP Annual Meeting
Expectations RA Patients Have For Their Treatment – A Comparison Of Clinical Results For Biologic and Disease-Modifying Anti-Rheumatic Drug Treated Patients Using Multiple Medical Cohorts
Background/Purpose: Treat to Target (T2T) primary principal - “The treatment of rheumatoid arthritis must be based on a shared decision between patient and rheumatologist”. Japan…Abstract Number: 1736 • 2013 ACR/ARHP Annual Meeting
A Randomized, Controlled, Multicenter, 2‑Arm, Parallel‑Group, Double-Blind Study To Demonstrate The Equivalence Of CT-P10 To Innovator Rituximab With Respect To Pharmacokinetic Profile In Patients With Rheumatoid Arthritis
Background/Purpose: CT-P10 was developed as a biosimilar candidate to innovator rituximab (RTX), an anti-CD20 monoclonal antibody. This trial is a phase I study to demonstrate…Abstract Number: 1697 • 2013 ACR/ARHP Annual Meeting
Are Patients With Rheumatoid Arthritis Still At An Increased Risk Of Tuberculosis and What Is The Role Of Biological Treatment?
Background/Purpose: Anti-TNF therapy is a risk factor for clinical tuberculosis (TB), which has led to pre-treatment screening and increased vigilance. The extent to which…Abstract Number: 1460 • 2013 ACR/ARHP Annual Meeting
10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes
Background/Purpose: Long term studies with treat-to-target therapy are essential to guide treatment strategies. We report on a study that compared clinical and radiological outcomes of…
ACR Meeting Abstracts